Respirics received FDA clearance this summer for its first product, MD Turbo™. The product is an accessory device that is designed for use by patients who use metered dose inhalers (MDI) known by many asthma sufferers as “puffers”. “This is a product that will immediately provide an option to help the more than 35 million people in the US with COPD and asthma” says William Nadel, Director of Market Development. “Studies have shown that up to 70% of people using MDIs can’t do it properly. Two of the biggest problems with these inhalers are that they are hard to use correctly and they don’t indicate to the patient how much medication remains. MD Turbo addresses both of these challenges.”

Respirics has announced that Series A funds will be used to advance a number of internal drug/device programs for the company’s Acu-Breathe™ dry powder inhaler. “It’s a very exciting time at Respirics right now. MD Turbo will be launched in the first quarter of 2006, and we could have pre-clinical work completed for one or more internal drug programs by the middle of next year” says Mott.